Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Tax Provisions (2020 - 2022)

Historic Tax Provisions for Rani Therapeutics Holdings (RANI) over the last 3 years, with Q4 2022 value amounting to -$11000.0.

  • Rani Therapeutics Holdings' Tax Provisions rose 7250.0% to -$11000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was -$11000.0, marking a year-over-year decrease of 11100.0%. This contributed to the annual value of $100000.0 for FY2022, which is 14390.24% up from last year.
  • Per Rani Therapeutics Holdings' latest filing, its Tax Provisions stood at -$11000.0 for Q4 2022, which was up 7250.0% from -$106000.0 recorded in Q3 2022.
  • Rani Therapeutics Holdings' Tax Provisions' 5-year high stood at $154000.0 during Q2 2022, with a 5-year trough of -$106000.0 in Q3 2022.
  • Over the past 3 years, Rani Therapeutics Holdings' median Tax Provisions value was $6000.0 (recorded in 2020), while the average stood at $14909.1.
  • In the last 5 years, Rani Therapeutics Holdings' Tax Provisions crashed by 43333.33% in 2021 and then skyrocketed by 1530000.0% in 2022.
  • Rani Therapeutics Holdings' Tax Provisions (Quarter) stood at $12000.0 in 2020, then tumbled by 433.33% to -$40000.0 in 2021, then skyrocketed by 72.5% to -$11000.0 in 2022.
  • Its Tax Provisions was -$11000.0 in Q4 2022, compared to -$106000.0 in Q3 2022 and $154000.0 in Q2 2022.